12th Jan 2026 09:29
(Alliance News) - Oxford Nanopore Technologies PLC on Monday said full year revenue growth will be ahead of previous expectations, reflecting broad-based growth across all geographies, customer end markets and product categories.
In response, shares in the Oxford-based specialist in DNA and RNA sequencing technologies shot up 6.2% to 149.50p each in London, the biggest riser on the FTSE 250 which itself was down 0.2%.
The company expects to report revenue of GBP223 million to GBP224 million in 2025, up as much as 22% from GBP183.2 million in 2024.
This represents growth of 24% at constant currency, slightly ahead of the group's guidance range of 20% to 23% constant currency growth, issued in September.
In a trading update, Oxford Nanopore highlighted continued commercial momentum with revenue increasing by more than 20% constant currency across each region.
Clinical revenue grew by 60% on a reported basis, BioPharma by 30% and Applied Industrial by 27%. Research revenue grew by 15% during the period despite end-market funding pressures.
Growth was delivered across all product types, led by the PromethION range, which grew by more than 40% year-on-year on a reported basis.
Year-end net cash was around GBP302 million, down from GBP403.8 million in 2024, but ahead of consensus expectations helped by improving working capital.
Oxford Nanopore will announce preliminary results for the twelve months ended December on March 2.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Nanopore Technologies